Drug intelligence / Profile preview

XS005 Sorafenib-ASD

Development stage: Phase 2
Lead developer: Xspray Pharma
Modality: Small Molecules
Administration: Oral

Overview

XS005 is a novel formulation of sorafenib, a multi-kinase inhibitor, utilizing a hybrid nanoparticle-amorphous solid dispersion (ASD) technology platform. This formulation is designed to enhance the absorption properties and reduce the pharmacokinetic variability of sorafenib, aiming for improved bioavailability and more consistent plasma exposure. Sorafenib itself is a tyrosine kinase inhibitor used in the treatment of various advanced cancers.

Other names: sorafenib-ASD

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on XS005 Sorafenib-ASD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XS005 Sorafenib-ASD.